The Joint Corp. (United States)

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US47973J1025
USD
8.45
0.18 (2.18%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Joint Corp. (United States) stock-summary
stock-summary
The Joint Corp. (United States)
Pharmaceuticals & Biotechnology
The Joint Corp develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. The Company has over 425 franchised, company-owned, or managed clinics in operation in over 30 states. In addition to its operating clinics, the Company has granted franchises either directly or through its regional developers for an additional over 170 clinics. The Company offers a range of membership and wellness packages. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
Company Coordinates stock-summary
Company Details
16767 N PERIMETER DRIVE, SUITE 110 , SCOTTSDALE AZ : 85260
stock-summary
Tel: 1 480 24559601 415 4333777
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 38 Schemes (21.41%)

Foreign Institutions

Held by 35 Foreign Institutions (5.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Peter Holt
President, Chief Executive Officer, Director
Mr. Matthew Rubel
Lead Independent Director
Mr. James Amos
Independent Director
Mr. Ronald DaVella
Independent Director
Ms. Suzanne Decker
Independent Director
Mr. Abe Hong
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
13 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 164 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.33

stock-summary
Return on Equity

-13.76%

stock-summary
Price to Book

7.04